UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (date of earliest event reported): ~~June~~October 57, ~~2024~~2025

Yijia Group Corp.

(Exact Name of Registrant as Specified in its Charter)

Nevada		333-218733		35-2583762
(State of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

39 E Broadway, Suite 603, New York, NY 10002

(Address of principal office)

+1-~~919~~516-~~869~~886-~~0279~~8888

(Registrant’s telephone number, including area code)

Not Applicable

(Former Name or former address if changed from last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class Trading Symbol(s) Name of each exchange on which registered ~~N/A~~Common ~~N/A~~Stock ~~N/A~~YJGJ OTC Pink Sheets

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 48.01 ~~Changes~~Other ~~in Registrant’s Certifying Accountant~~Events.

OnYijia ~~June~~Group 5,Corp. ~~2024,~~ (the “Company”) has ~~elected~~proposed ~~not~~ to ~~continue~~change the ~~engagement~~name of ~~Olayinka~~the ~~Oyebola~~Company &to ~~Co.~~VitaNova Life Sciences Corporation (the “OOName ~~& Co.~~Change”). The Name ~~serving~~Change aswas approved by the ~~Company’s~~Board ~~independent~~of ~~registered~~Directors ~~public~~of ~~accounting~~the ~~firm.~~Company ~~The~~(the ~~termination~~“Board”) ofand ~~the~~a ~~engagement~~majority of ~~OO &~~the ~~Co.~~holders ~~was~~of ~~approved~~all by of the ~~Company’s~~issued ~~board~~and outstanding shares of ~~directors~~common ~~(the~~stock (“~~Board~~Common Stock”) of the Company.

~~The~~In ~~reports~~connection ofwith ~~OO & Co. on~~ the ~~financial~~Name ~~statements of the Company as of April 30~~Change, ~~2023 and 2022 and for~~ the ~~fiscal years ended April 30, 2023~~Company ~~and~~intends ~~2022~~to ~~did~~change ~~not~~its ~~contain~~ticker ~~any~~symbol ~~adverse~~with ~~opinion~~OTC orMarkets ~~disclaimer~~Group ofInc. ~~opinion~~Until ~~and~~the ~~were~~new ~~not~~ticker ~~qualified~~symbol orbecomes ~~modified as to uncertainty~~effective, ~~audit~~the ~~scope~~Company’s Common orStock ~~accounting~~will ~~principles,~~continue ~~other~~to ~~than~~trade anunder ~~explanatory~~its ~~paragraph~~current ~~regarding~~ticker ~~the~~symbol ~~substantial~~and ~~doubt~~CUSIP ~~about the Company’s ability to continue as a going concern~~number.

~~During~~The ~~the~~Company ~~fiscal~~has ~~years~~also ~~ended~~proposed ~~April~~to ~~30,~~effect ~~2022~~a ~~and~~reverse ~~2023~~stock ~~and~~split ~~the~~at ~~subsequent~~a ~~interim~~ratio ~~period~~within ~~through~~the ~~June~~range 4,from ~~2024~~1-for-2 to 1-for-3, ~~there~~such ~~were~~that noeach ~~disagreements~~holder ~~with~~of OOCommon &Stock ~~Co.~~of onthe ~~any~~Company ~~matter~~shall ofreceive ~~accounting~~one ~~principles~~(1) orshare ~~practices,~~of ~~financial~~Common ~~statement~~Stock ~~disclosure,~~for orevery ~~auditing~~two ~~scope~~(2) or ~~procedure,~~three ~~which disagreement~~(s3), ifshares ~~not~~of ~~resolved~~Common toStock (the ~~satisfaction~~ of“Reverse ~~OO & Co~~Split”)., ~~would~~The ~~have caused it to make reference to the subject matter~~Reverse ofSplit ~~the~~was ~~disagreement(s)~~approved inby ~~connection with its report. During~~ the ~~fiscal~~Board ~~years ended April 30, 2022~~ and ~~2023~~a ~~and~~majority of the ~~subsequent~~holders ~~interim period~~of ~~through~~all ~~June 4, 2024, there were no reportable events~~ of the ~~type~~issued ~~described~~and inoutstanding ~~Item~~shares ~~304(a)(1)(v)~~ of ~~Regulation~~Common ~~S-K~~Stock.

~~The~~Additionally, the Company ~~provided~~has proposed to increase OOits &authorized ~~Co.~~capital ~~with~~to a85,000,000 ~~copy~~shares of ~~the~~capital ~~foregoing~~stock, ~~disclosure~~consisting of 75,000,000 shares of Common Stock and ~~requested~~10,000,000 OOshares of &preferred Costock, $0.0001 topar ~~furnish~~value ~~the~~per ~~Company~~share ~~with~~(the a“Share ~~letter~~Capital ~~addressed~~Increase”), toand authorized the ~~Securities~~creation of blank check preferred stock, with such series, designations, rights and ~~Exchange~~preferences ~~Commission~~as ~~stating~~may ~~whether~~be itestablished ~~agrees~~from ~~with~~ time to time by the ~~statements~~Board ~~made~~(the ~~therein~~“Preferred Stock Designation”). AThe ~~copy~~Share ofCapital ~~such~~Increase ~~letter~~and ~~furnished~~Preferred Stock Designation were approved by OOthe &Board ~~Co.~~the isa ~~filed~~majority asof ~~Exhibit~~the ~~16.1~~holders toof ~~this~~all ~~Form~~of ~~8-K~~the issued and outstanding shares of Common Stock.

OnThe ~~June~~Company 5,is ~~2024,~~currently ~~the~~evaluating and finalizing ~~Board~~the ~~approved~~ratio for the ~~engagement~~proposed reverse stock split. Following the determination of ~~Simon~~the &reverse ~~Edward~~split ratio, ~~LLP~~the ~~(“S&E”)~~Company asintends to file a Certificate of Amendment to its Articles of Incorporation with the ~~Company’s~~Nevada ~~new~~Secretary ~~independent~~of ~~registered~~State ~~public~~to effect the Name Change, the Reverse Split, ~~accounting~~the ~~firm~~Share Capital Increase and the Preferred Stock Designation.

During the Company’s two most recent fiscal years and the subsequent interim period through June 4, 2024, neither the Company nor anyone on its behalf consulted with S&E regarding (i) the application of accounting principles to a specified transaction, either completed or proposed; the type of audit opinion that might be rendered on the Company’s financial statements, and neither a written report nor oral advice was provided that S&E concluded was an important factor considered by the Company in reaching a decision as to the accounting, auditing or financial reporting issue; or (ii) any matter that was either the subject of a disagreement (as defined in Item 304(a)(1)(iv) of Regulation S-K and its related instructions) or a reportable event (as described in Item 304(a)(1)(v) of Regulation S-K).2

~~Item 9.01 Financial Statements and Exhibits.~~SIGNATURE

Exhibit Number		Description
16.1		Letter from Olayinka Oyebola & Co., dated June 10, 2024
104		Cover Page Interactive Data File formatted in inline XBRL

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

2Date: October 7, 2025

~~SIGNATURE~~YIJIA Group Corp. By: /s/ Qiuping Lu Qiuping Lu Chief Executive Officer and Director (Principal Executive Officer)

~~Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.~~3

Date: June 10, 2024

YIJIA Group Corp. By: /s/ Qiuping Lu Qiuping Lu Chief Executive Officer and Director (Principal Executive Officer)

Filing Compare · VitaNova Life Sciences Corp